Beijing Biostar Pharmaceuticals Co (HKSE:02563) Total Receivables: HK$72.94 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02563 Beijing Biostar Pharmaceuticals Co Ltd HKSE:02563
9 GF Score
Price HK$3.40
! 4 Warning Signs
View Full Analysis

What is Beijing Biostar Pharmaceuticals Co Total Receivables?

Beijing Biostar Pharmaceuticals Co HKSE:02563 -4.23% 9 Total Receivables is HK$72.94 Mil as of Dec. 2025. GuruFocus rates HKSE:02563 with a GF Score™ of 9/100. The stock has 4 warning signs investors should review.

Beijing Biostar Pharmaceuticals Co's Total Receivables for the quarter that ended in Dec. 2025 was HK$72.94 Mil.

Beijing Biostar Pharmaceuticals Co Total Receivables Related Terms

Beijing Biostar Pharmaceuticals Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Beijing Biostar Pharmaceuticals Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Biostar Pharmaceuticals Co Total Receivables Chart

Beijing Biostar Pharmaceuticals Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Receivables
39.16 12.75 25.63 72.94

Beijing Biostar Pharmaceuticals Co Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial 12.75 0.00 25.63 53.76 72.94
HKSE:02563
9GF Score
Beijing Biostar Pharmaceuticals Co Ltd HKSE:02563
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Biostar Pharmaceuticals Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of HK$72.94 Mil mean?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a Total Receivables of HK$72.94 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors.
Is Beijing Biostar Pharmaceuticals Co's Total Receivables too high?
Beijing Biostar Pharmaceuticals Co's current Total Receivables is HK$72.94 Mil. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's Total Receivables compare to VRTX and REGN?
Beijing Biostar Pharmaceuticals Co's Total Receivables of HK$72.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. Beijing Biostar Pharmaceuticals Co's current Total Receivables is HK$72.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current Total Receivables of HK$72.94 Mil. The current Total Receivables is HK$72.94 Mil. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current Total Receivables is HK$72.94 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beijing Biostar Pharmaceuticals Co Business Description

Address 22 Ronghua Middle Road, Suite 1202, Tower B, Yicheng Fortune Center, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score

Get the complete analysis for HKSE:02563

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.40
Price